Introduction {#section5-2042018819842971}
============

The prevalence of type 2 diabetes mellitus (T2DM) is increasing in the elderly population, and the management of elderly patients with T2DM is a critical issue. In the ageing population, sarcopenia is a serious complication related to the progressive loss of skeletal muscle mass and function as it causes frailty that results in elderly patients becoming bedridden.^[@bibr1-2042018819842971]^ Accumulating evidence has shown that patients with T2DM are at an increased risk of sarcopenia.^[@bibr2-2042018819842971][@bibr3-2042018819842971]--[@bibr4-2042018819842971]^ Although the pathophysiological mechanism underlying T2DM-associated sarcopenia remains unclear, the dysfunction of insulin and insulin-like growth factor 1, as well as advanced glycation end products, which are generated by the sequential nonenzymatic chemical glycation of proteins^[@bibr5-2042018819842971]^ and are increased in patients with T2DM,^[@bibr6-2042018819842971]^ may be associated with the mechanism of T2DM-associated sarcopenia.^[@bibr7-2042018819842971][@bibr8-2042018819842971]--[@bibr9-2042018819842971]^ Moreover, skeletal muscle is an important tissue involved in insulin action and glucose metabolism. Thus, the disturbance of glucose metabolism in T2DM may lead to the loss of skeletal muscle and vice versa. Therefore, sarcopenia has recently been recognized as a diabetic complication.

T2DM reduces the life expectancy of patients.^[@bibr10-2042018819842971]^ The adjusted relative risk of death has been reported to be almost twice as high in patients with diabetes mellitus compared with that in age-matched controls.^[@bibr11-2042018819842971]^ Furthermore, the presence of T2DM increases the risks of cardiovascular diseases,^[@bibr10-2042018819842971]^ infections,^[@bibr12-2042018819842971]^ cancer,^[@bibr13-2042018819842971]^ and fractures,^[@bibr14-2042018819842971]^ all of which are associated with increased mortality. However, whether other diabetic complications contribute to the increased mortality in patients with T2DM remains unclear. Studies have demonstrated that low skeletal muscle mass is associated with an increased risk of all-cause mortality in the elderly population.^[@bibr15-2042018819842971]^ Therefore, we hypothesized that low skeletal muscle mass is associated with mortality in patients with T2DM. Thus far, no study has focused on the association between muscle mass and mortality risk in patients with T2DM. Therefore, this study aimed to examine the association of body composition, skeletal muscle mass index (SMI), and all-cause mortality in patients with T2DM.

Materials and methods {#section6-2042018819842971}
=====================

Patients {#section7-2042018819842971}
--------

In this historical cohort study, we investigated the association between lean body mass (LBM) and the endpoint of all-cause mortality in patients with T2DM. Patients admitted to Shimane University Hospital, Japan, for the treatment of T2DM, except those with malignant diseases, infections, necessity of surgery, and other special conditions, from 1997 to 2009 were screened. According to hospital records, 843 men and 667 women were admitted. We investigated patient survival or mortality based on medical records and telephone surveys from 2013 to 2014. Based on the data, the body composition was evaluated using whole-body dual-energy X-ray absorptiometry (DXA) at the baseline, and a survey of life and death was available for 163 men and 141 postmenopausal women with T2DM. The median follow-up periods were 5.9 and 6.2 years in men and women, respectively. This study was approved by the institutional review board (IRB) of the Faculty of Medicine at Shimane University (IRB approval number 2958). The requirement for informed patient consent was waived because no interventions or further examinations were performed.

Anthropometric and biochemical measurements {#section8-2042018819842971}
-------------------------------------------

Body height (cm) was measured using the Martin metal anthropometer to the nearest 0.1 cm according to standard techniques, and body weight (kg) was measured using a medical electronic scale and recorded with 0.05-kg precision with the patient wearing lightweight clothes. Body mass index (BMI; kg/m^2^) was calculated using the following formula: BMI = (weight in kg)/\[(height in m)^2^\]. After overnight fasting, blood and urine samples were collected the day after admission. Hemoglobin A1c (HbA1c), serum fasting C-peptide, and serum creatinine levels were measured using standard biochemical methods, as previously reported.^[@bibr7-2042018819842971],[@bibr8-2042018819842971]^ HbA1c values were determined by high-performance liquid chromatography and were estimated as the National Glycohemoglobin Standardization Program equivalent values calculated using the formula: HbA1c (%) = HbA1c (Japan Diabetes Society; %) + 0.4%.

Radiography {#section9-2042018819842971}
-----------

Body composition was assessed using whole-body DXA (QDR-4500, Hologic Co., Bedford, MA, USA). Fat mass (FM), bone mineral content (BMC), and LBM were expressed in kilograms. LBM of the arms and legs and appendicular skeletal muscle mass (ASM) was evaluated. SMI was calculated using the following formula: SMI = (ASM in kg)/\[(height in m)^2^\], as previously described.^[@bibr7-2042018819842971],[@bibr8-2042018819842971]^ Low SMI was defined as \<7.0 kg/m^2^ for men and \<5.4 kg/m^2^ for women, which are used for the diagnosis of sarcopenia in Asian individuals.^[@bibr16-2042018819842971]^

Statistical analysis {#section10-2042018819842971}
--------------------

Data were expressed as means ± standard deviations (SDs). The statistical significance between the two groups was determined using Student's *t* test and Chi-square tests. Kaplan--Meier curves, log-rank tests, and Cox proportional hazard regression analyses were used to estimate the associations among body composition, SMI, and the risk of mortality after adjusting for confounding factors such as age, duration of diabetes, HbA1c, serum creatinine, fasting C-peptide, and BMI. All analyses were performed using StatView (Abacus Concepts, Berkeley, CA, USA). A *p* value \<0.05 was considered statistically significant.

Results {#section11-2042018819842971}
=======

Baseline characteristics of the patients and comparison between dead and surviving patients {#section12-2042018819842971}
-------------------------------------------------------------------------------------------

Baseline characteristics of the patients (163 men and 141 women) and a comparison between survivors (131 men and 32 women) and dead patients (32 men and 14 women) are shown in [Table 1](#table1-2042018819842971){ref-type="table"}. Among men, dead patients were significantly older than survivors (*p* \< 0.001). The BMC, LBM, and SMI of dead patients were significantly lower than those of survivors (*p* = 0.002, *p* \< 0.001, and *p* = 0.004, respectively). Among women, dead patients were significantly older (*p* \< 0.001) and had longer durations of T2DM (*p* = 0.021). BMI, fasting C-peptide, FM, BMC, LBM, and SMI of dead patients were significantly lower than those of survivors (*p* = 0.011, *p* = 0.005, *p* = 0.008, *p* = 0.015, *p* \< 0.001, and *p* = 0.037, respectively). The numbers of patients who received insulin, sulfonylurea, metformin, and thiazolidine were 26, 56, 22, and 19 men, respectively, and 41, 47, 27, and 12 women, respectively. The numbers of patients with a history of cardiovascular disease and stroke were 19 and 12 men, respectively, and 11 and 14 women, respectively.

###### 

Baseline characteristics and comparison between dead patients and survivors.

![](10.1177_2042018819842971-table1)

                                 Men           Women                                                                           
  ------------------------------ ------------- ------------- ------------- --------- ------------- ------------- ------------- ---------
  Age (years)                    64.4 ± 9.3    63.0 ± 9.1    70.4 ± 7.4    \<0.001   66.1 ± 9.9    65.1 ± 9.6    75.1 ± 8.9    \<0.001
  Duration of diabetes (years)   10.6 ± 9.9    10.7 ± 9.8    10.5 ± 10.8   0.935     11.6 ± 10.2   10.9 ± 9.8    17.7 ± 1018   0.021
  BMI (kg/m²)                    23.0 ± 3.2    23.2 ± 3.1    22.3 ± 3.3    0.147     24.7 ± 4.5    24.9 ± 4.4    22.7 ± 4.9    0.011
  HbA1c (%)                      8.9 ± 2.1     8.8 ± 2.1     9.0 ± 2.3     0.668     8.9 ± 2.2     8.8 ± 2.2     9.5 ± 2.4     0.332
  Serum creatinine (mg/dl)       0.80 ± 0.23   0.78 ± 0.22   0.87 ± 0.27   0.054     0.65 ± 0.29   0.66 ± 0.30   0.57 ± 0.13   0.240
  Fasting C-peptide (ng/ml)      1.7 ± 1.0     1.7 ± 1.0     1.6 ± 1.0     0.613     1.7 ± 0.8     1.7 ± 0.8     1.1 ± 0.5     0.005
  FM (kg)                        12.3 ± 4.5    12.6 ± 4.3    11.0 ± 4.8    0.064     17.1 ± 6.4    17.6 ± 6.25   12.8 ± 6.6    0.008
  BMC (kg)                       2.2 ± 0.4     2.2 ± 0.4     2.0 ± 0.3     0.002     1.5 ± 0.3     1.6 ± 0.3     0.4 ± 0.4     0.015
  LBM (kg)                       46.1 ± 5.9    46.9 ± 5.6    42.8 ± 5.9    \<0.001   36.6 ± 5.1    37.2 ± 5.0    3.1 ± 3.1     \<0.001
  SMI (kg/m^2^)                  7.14 ± 0.86   7.23 ± 0.83   6.74 ± 0.89   0.004     6.40 ± 0.88   6.47 ± 0.85   5.76 ± 0.93   0.037
  Insulin                        26            20            6             0.645     41            36            5             0.581
  Sulfonylurea                   56            45            11            0.980     47            42            5             0.859
  Metformin                      22            20            2             0.179     27            26            1             0.228
  Thiazolidine                   19            14            5             0.448     12            11            1             0.842
  Statin                         27            22            5             0.180     52            48            4             0.487
  ACEi/ARB                       24            20            4             0.319     48            45            2             0.126
  Calcium antagonists            26            20            6             0.860     42            40            2             0.192
  Anti-platelet drugs            35            27            8             0.709     28            28            0             \-
  CVD                            19            13            6             0.663     11            11            0             \-
  Stroke                         12            11            1             0.588     14            13            1             0.715

ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BMC, bone mineral content; BMI, body mass index; CVD, cardiovascular disease; FM, fat mass; HbA1c, glycated hemoglobin; LBM, lean body mass; SMI, skeletal muscle mass index.

Association between body composition and all-cause mortality {#section13-2042018819842971}
------------------------------------------------------------

In the unadjusted Cox regression analysis, LBM was significantly and inversely associated with all-cause mortality in men \[hazard ratio (HR) = 2.19, 95% confidence interval (CI) = 1.49--3.22 per SD decrease, *p* \< 0.001\] and women (HR = 4.95, 95% CI = 2.10--11.67 per SD decrease, *p* \< 0.001) ([Table 2](#table2-2042018819842971){ref-type="table"}). After adjustment for age, duration of T2DM, HbA1c, serum creatinine, and serum fasting C-peptide (Model 1), LBM was significantly associated with mortality in men (HR = 1.73, 95% CI = 1.10--2.72 per SD decrease, *p* = 0.018) and in women (HR = 3.06, 95% CI = 1.17--8.02 per SD decrease, *p* = 0.023). Moreover, after additional adjustments for BMI (Model 2), LBM was still significantly associated with mortality in men (HR = 1.81, 95% CI = 1.00--3.28 per SD decrease, *p* = 0.049) and women (HR = 4.53, 95% CI = 1.14--17.96 per SD decrease, *p* = 0.032). In contrast, in the unadjusted analysis, lower FM and lower BMC values were associated with increased mortality in men and women, whereas the association became insignificant after adjustment (Models 1 and 2).

###### 

Association between body composition and mortality.

![](10.1177_2042018819842971-table2)

             Men    Women                                       
  ---------- ------ ------------ --------- ------ ------------- ---------
  LBM                                                           
   Crude     2.19   1.49--3.22   \<0.001   4.95   2.10--11.67   \<0.001
   Model 1   1.73   1.10--2.72   0.018     3.06   1.17--8.02    0.023
   Model 2   1.81   1.00--3.28   0.049     4.53   1.14--17.96   0.032
  FM                                                            
   Crude     1.69   1.10--2.62   0.018     2.82   1.38--5.75    0.005
   Model 1   1.53   0.92--2.56   0.104     1.74   0.69--4.37    0.238
   Model 2   1.47   0.70--3.08   0.309     1.42   0.27--7.43    0.679
  BMC                                                           
   Crude     1.76   1.24--2.48   0.001     1.99   1.09--3.60    0.024
   Model 1   1.45   0.94--2.24   0.095     1.16   0.56--2.44    0.688
   Model 2   1.37   0.86--2.16   0.182     0.96   0.42--2.16    0.912

Cox proportional hazard regression models were performed with all-cause mortality as a dependent variable and SMI as an independent variable.

Model 1; adjusted for age, duration of diabetes, HbA1c, serum creatinine, and fasting C-peptide Model 2; adjusted for model 1 plus BMI.

Unit of change; standard deviation per decrease.

BMC, bone mineral content; BMI, body mass index; CI, confidential interval; FM, fat mass; HbA1c, glycated hemoglobin; HR, hazard ratio; LBM, lean body mass; SMI, skeletal muscle mass index.

Association between SMI and all-cause mortality {#section14-2042018819842971}
-----------------------------------------------

Next, the background characteristics were compared between patients with and without low SMI ([Table 3](#table3-2042018819842971){ref-type="table"}). In men, patients with low SMI (\<7.0 kg/m^2^) had significantly lower BMI and lower serum fasting C-peptide levels than those without low SMI (*p* \< 0.001 and *p* = 0.021, respectively). In women, patients with low SMI (\<5.4 kg/m^2^) had significantly lower BMI than those without low SMI (*p* \< 0.001).

###### 

Comparison of various parameters between patients with and without low SMI.

![](10.1177_2042018819842971-table3)

                                 Men           Women                                               
  ------------------------------ ------------- ------------- --------- ------------- ------------- ---------
  Number of patients             94            69                      124           17            
  Age (years)                    63.9 ± 9.8    65.2 ± 8.4    0.402     66.2 ± 10.0   65.6 ± 9.6    0.840
  Duration of diabetes (years)   10.7 ± 10.0   10.6 ± 9.9    0.972     11.3 ± 9.6    13.3 ± 13.6   0.460
  BMI (kg/m²)                    24.6 ± 2.6    20.8 ± 2.5    \<0.001   25.3 ± 4.4    20.1 ± 2.4    \<0.001
  HbA1c (%)                      8.6 ± 2.0     9.2 ± 2.3     0.131     8.9 ± 2.2     8.7 ± 2.2     0.726
  Serum creatinine (mg/dl)       0.80 ± 0.23   0.80 ± 0.24   0.858     0.61 ± 0.14   0.66 ± 0.30   0.483
  Fasting C-peptide (ng/ml)      1.8 ± 1.1     1.4 ± 0.7     0.021     1.7 ± 0.8     1.5 ± 0.6     0.342
  SMI (kg/m^2^)                  7.72 ± 0.57   6.35 ± 0.47   \<0.001   6.59 ± 0.74   4.99 ± 0.41   \<0.001
  Insulin                        13            13            0.408     36            5             0.990
  Sulfonylurea                   25            21            0.344     42            5             0.701
  Metformin                      16            6             0.120     27            0             \-
  Thiazolidine                   12            7             0.592     11            1             0.675
  Statin                         18            9             0.289     50            2             0.035
  ACEi/ARB                       12            12            0.571     45            2             0.059
  Calcium antagonists            15            11            0.743     40            2             0.098
  Anti-platelet drugs            18            17            0.400     26            2             0.380
  CVD                            13            6             0.295     9             2             0.520
  Stroke                         7             5             0.931     14            0             \-

ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BMI, body mass index; CVD, cardiovascular disease; HbA1c, glycated hemoglobin; SMI, skeletal muscle mass index.

Unadjusted survival analyses indicated that patients with low SMI had higher mortality than those with high SMI, both in men and women (*p* = 0.008 and *p* = 0.014, respectively; [Figure 1](#fig1-2042018819842971){ref-type="fig"} and [Table 4](#table4-2042018819842971){ref-type="table"}). In the Cox regression analysis adjusted for age, duration of T2DM, HbA1c, serum creatinine, and serum fasting C-peptide (Model 1), low SMI was significantly and positively associated with mortality in men (HR = 2.46, 95% CI = 1.13--5.37, *p* = 0.023) and women (HR = 6.20, 95% CI = 1.46--26.28, *p* = 0.013). The association remained significant even after adjusting for BMI (Model 2) in women (HR = 5.97, 95% CI 1.04--34.37, *p* = 0.045), but the association became marginal in men (HR = 2.38, 95% CI 0.92--6.14, *p* = 0.074).

![Survival curves of high and low SMI in men (a) and women (b) with type 2 diabetes mellitus.\
SMI, skeletal muscle mass index.](10.1177_2042018819842971-fig1){#fig1-2042018819842971}

###### 

HRs stratified by low SMI.

![](10.1177_2042018819842971-table4)

            Men    Women                                     
  --------- ------ ------------ ------- ------ ------------- -------
  Crude     2.58   1.25--5.32   0.010   4.00   1.20--13.30   0.024
  Model 1   2.46   1.13--5.37   0.023   6.20   1.46--26.28   0.013
  Model 2   2.38   0.92--6.14   0.074   5.97   1.04--34.37   0.045

Cox proportional hazard regression models were performed with all-cause mortality as a dependent variable and SMI as an independent variable.

Model 1; adjusted for age, duration of diabetes, HbA1c, serum creatinine, and fasting C-peptide.

Model 2; adjusted for model 1 plus BMI.

BMI, body mass index; CI, confidential interval; HbA1c, glycated hemoglobin; HR, hazard ratio; SMI, skeletal muscle mass index.

Discussion {#section15-2042018819842971}
==========

Previous studies have demonstrated that low muscle mass is associated with an increased risk of mortality.^[@bibr15-2042018819842971],[@bibr17-2042018819842971][@bibr18-2042018819842971]--[@bibr19-2042018819842971]^ However, to date, no study has examined the association between muscle mass and mortality in patients with T2DM. Therefore, this is the first study to reveal that LBM is inversely associated with the risk of all-cause mortality in Japanese patients with T2DM and that low SMI based on the criteria of the Asian Working Group for Sarcopenia is associated with mortality risk. Moreover, the association was independent of age, duration of T2DM, HbA1c, serum creatinine, serum C-peptide, and BMI. Therefore, muscle mass reduction is an important predictor of all-cause mortality in patients with T2DM.

The present study revealed that low LBM was associated with increased mortality even after adjusting for BMI. Chuang and colleagues previously reported that the lowest quartile of SMI was associated with the highest all-cause mortality in the elderly Chinese population after adjusting for various confounding factors, including BMI.^[@bibr15-2042018819842971]^ Moreover, weight loss is a risk factor for poor prognosis among elderly individuals. In this study, LBM was independently associated with mortality risk, whereas FM was not associated with mortality risk. These findings suggest that muscle mass reduction, but not FM, may be the cause of increased mortality in patients with T2DM.

In this study, the association between low muscle mass and increased mortality was more prominent in postmenopausal women than in men. Batsis and colleagues showed that women with sarcopenia, which is defined by magnetic resonance imaging-measured skeletal mass, had a higher mortality risk than those without sarcopenia, whereas the presence of sarcopenia was not associated with mortality in men.^[@bibr17-2042018819842971]^ Chuang and colleagues also reported that low SMI appeared to be more tightly associated with high mortality in women than in men.^[@bibr15-2042018819842971]^ Thus, our findings are consistent with those of previous studies. The underlying mechanism of muscle mass reduction may differ between men and women. In this study, we did not examine sex hormones and binding proteins, which might be involved in the difference in sex. Furthermore, the causes of death could be different between men and women with T2DM. The causes of death, such as cardiovascular conditions, infections, and malignant diseases, were not available in this study because the information was obtained from hospital records and telephone surveys. Further investigations should be performed to assess the relationship between muscle mass and cause of death in men and women with T2DM in the future.

However, muscle quality has recently been considered important, especially in patients with T2DM. Park and colleagues showed that muscle quality, defined as muscle strength per unit of regional muscle mass, was significantly lower in patients with T2DM, although patients with T2DM had greater muscle mass than healthy people because they had a larger body size.^[@bibr2-2042018819842971]^ Moreover, leg muscle quality declined more rapidly in patients with T2DM than in healthy people.^[@bibr18-2042018819842971]^ In this study, muscle functions such as handgrip and gait speed were not evaluated. Further studies should be performed to clarify whether muscle function and quality are associated with an increased all-cause mortality risk in men and women with T2DM.

The present study had several limitations. First, the sample size was not large enough to make definite conclusions. Because we could not follow up several patients, some patients lost to follow up may have died. Second, we examined only those patients who visited Shimane University Hospital, a tertiary center for the evaluation or treatment of T2DM. Therefore, the patients enrolled in this study might have relatively severe diseases. Third, the retrospective study design was an important limitation. Although several potential confounders were adjusted for, selection bias could affect the present findings. Moreover, comorbidities could be associated with muscle mass reduction and mortality. Because of the small number of patients with a history of cardiovascular or stroke, these comorbidities could not be included in the analysis. Further large-scale prospective studies are necessary to confirm the independent association between muscle mass reduction and mortality risk. Fourth, data such as those regarding HbA1c during the follow-up period were lacking. Finally, nondiabetic controls were not examined in this study. Therefore, we could not compare the contribution of muscle mass reduction to mortality between patients with T2DM and nondiabetic people. Conversely, we evaluated the association between not only LBM but also FM and all-cause mortality risk. Moreover, we examined the BMI-independent association between muscle mass and mortality. Thus, we should consider body composition rather than BMI when assessing the life expectancy of patients with T2DM. Furthermore, we used the cut-off value of SMI according to the criteria of the Asian Working Group for Sarcopenia.^[@bibr16-2042018819842971]^ The findings of our study indicate that SMI might be useful not only for defining sarcopenia but also for predicting the all-cause mortality risk in patients with T2DM.

In conclusion, the present study showed that lower LBM and lower SMI were associated with increased all-cause mortality independent of age, duration of T2DM, HbA1c, renal function, insulin secretion, and BMI in patients with T2DM. Therefore, the preservation of skeletal muscle mass is an important factor in the protection of patients with T2DM from increased mortality risk.
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